These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26218540)

  • 1. Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice.
    Morentin Gutierrez P; Gyte A; deSchoolmeester J; Ceuppens P; Swales J; Stacey C; Eriksson JW; Sjöstrand M; Nilsson C; Leighton B
    Br J Pharmacol; 2015 Oct; 172(20):4806-16. PubMed ID: 26218540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of 11β-hydroxysteroid dehydrogenase 1 kinetics and pharmacodynamic effects of inhibitors in brain using mass spectrometry imaging and stable-isotope tracers in mice.
    Cobice DF; Livingstone DEW; McBride A; MacKay CL; Walker BR; Webster SP; Andrew R
    Biochem Pharmacol; 2018 Feb; 148():88-99. PubMed ID: 29248595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329).
    Scott JS; deSchoolmeester J; Kilgour E; Mayers RM; Packer MJ; Hargreaves D; Gerhardt S; Ogg DJ; Rees A; Selmi N; Stocker A; Swales JG; Whittamore PR
    J Med Chem; 2012 Nov; 55(22):10136-47. PubMed ID: 23088558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye.
    Anderson S; Carreiro S; Quenzer T; Gale D; Xiang C; Gukasyan H; Lafontaine J; Cheng H; Krauss A; Prasanna G
    J Ocul Pharmacol Ther; 2009 Jun; 25(3):215-22. PubMed ID: 19456256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
    Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
    Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms.
    Harno E; Cottrell EC; Yu A; DeSchoolmeester J; Gutierrez PM; Denn M; Swales JG; Goldberg FW; Bohlooly-Y M; Andersén H; Wild MJ; Turnbull AV; Leighton B; White A
    Endocrinology; 2013 Dec; 154(12):4580-93. PubMed ID: 24169553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol inhibits 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose microsomes.
    Tagawa N; Kubota S; Kato I; Kobayashi Y
    J Endocrinol; 2013 Sep; 218(3):311-20. PubMed ID: 23814014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
    Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
    Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
    Masuzaki H; Flier JS
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.
    Gibbs JP; Emery MG; McCaffery I; Smith B; Gibbs MA; Akrami A; Rossi J; Paweletz K; Gastonguay MR; Bautista E; Wang M; Perfetti R; Daniels O
    J Clin Pharmacol; 2011 Jun; 51(6):830-41. PubMed ID: 20663992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
    Ge R; Huang Y; Liang G; Li X
    Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11β-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue.
    Tagawa N; Minamitani E; Yamaguchi Y; Kobayashi Y
    Steroids; 2011 Dec; 76(14):1546-53. PubMed ID: 21945397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
    Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
    J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
    Stimson RH; Andrew R; McAvoy NC; Tripathi D; Hayes PC; Walker BR
    Diabetes; 2011 Mar; 60(3):720-5. PubMed ID: 21266326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1.
    Jean DJ; Yuan C; Bercot EA; Cupples R; Chen M; Fretland J; Hale C; Hungate RW; Komorowski R; Veniant M; Wang M; Zhang X; Fotsch C
    J Med Chem; 2007 Feb; 50(3):429-32. PubMed ID: 17266194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
    Hong SP; Han D; Chang KH; Ahn SK
    Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzofuran derivatives inhibit 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose tissue.
    Kiyonaga D; Tagawa N; Yamaguchi Y; Wakabayashi M; Kogure T; Ueda M; Miyata O; Kobayashi Y
    Biol Pharm Bull; 2012; 35(8):1275-80. PubMed ID: 22863925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.
    Tomlinson JW; Sherlock M; Hughes B; Hughes SV; Kilvington F; Bartlett W; Courtney R; Rejto P; Carley W; Stewart PM
    J Clin Endocrinol Metab; 2007 Mar; 92(3):857-64. PubMed ID: 17200165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.